PepRecs

Compounded vs FDA-approved GLP-1s

Last updated Aug 1, 2026

This is the single most important distinction when comparing GLP-1 providers. Here it is in plain language.

Is compounded semaglutide or tirzepatide legal right now?

Compounded semaglutide and tirzepatide are not FDA-approved, and the broad legal basis that made them widely available has closed. FDA declared the shortages resolved, which ended the shortage-based exception that let compounders supply them at scale. Large-scale compounding by 503B outsourcing facilities is now the subject of an FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, on the basis that FDA identified no clinical need for it; the public comment period closed on July 30, 2026 and a final decision is pending. Narrow patient-specific (503A) compounding can still be lawful in limited circumstances, for example a documented allergy to an ingredient in the approved product, or a dose the approved product doesn't come in, but a compounded drug that is essentially a copy of an available FDA-approved product is not permitted. Whether any specific prescription is lawful depends on your prescriber, the pharmacy, and your state; this is not legal or medical advice.

Checked against primary sources on Aug 1, 2026. Regulatory status changes, confirm before relying on it. Not legal or medical advice.

How it got here

Each entry is a thing a regulator actually did, on the date it did it, linked to the primary record.

  1. Feb 21, 2025

    FDA declared the semaglutide shortage resolved, ending the shortage-based basis for compounding it at scale.

    FDA

  2. May 22, 2025

    Deadline for 503B outsourcing facilities to stop compounding semaglutide following the shortage resolution.

    FDA

  3. May 1, 2026

    FDA published a Federal Register notice proposing NOT to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, stating it identified no clinical need for outsourcing facilities to compound them from bulk substances.

    Federal Register

  4. Jun 26, 2026

    FDA extended the public comment period on that proposal to July 30, 2026.

    Federal Register

  5. Jul 30, 2026

    Comment period closed. FDA's final determination had not been published as of this review, so the 503B exclusion remains PROPOSED rather than final.

    FDA proposal

What this means if you're buying

  • A compounded GLP-1 is not an FDA-approved product. It has not been reviewed by FDA for safety, effectiveness, or manufacturing quality, whatever the provider's marketing says.
  • Supply has narrowed and can change quickly. Several telehealth brands have already exited compounded semaglutide, so a provider offering it today may not offer it next quarter, check before prepaying for a multi-month plan.
  • Ask which pharmacy compounds it and whether that pharmacy is a 503A pharmacy or a 503B outsourcing facility. A provider unwilling to name it is telling you something.
  • If a compounded product is being offered to you simply because it is cheaper than the approved drug, that is the fact pattern FDA has said is not permitted, a compounded copy of an available approved product.

FDA-approved products

Branded semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and the oral pill orforglipron (Foundayo) are FDA-approved. They are manufactured under FDA oversight with a known, consistent formulation. After cash-pay prices fell in 2025–2026, FDA-approved options are often close to, or cheaper than, compounded ones.

Compounded products

Compounded semaglutide and tirzepatide are mixed by a pharmacy and are not FDA-approved. During the 2022–2024 shortage they were widely available. The FDA declared both shortages resolved (tirzepatide in late 2024, semaglutide in early 2025), and enforcement discretion for mass compounding ended in 2025.

As of 2026, compounding is legal only on a narrow, patient-specific basis (the 503A pathway) when a clinician documents a medical need the FDA-approved product can't meet. The FDA has sent multiple waves of warning letters to telehealth companies that marketed compounded GLP-1s as equivalent to the brand or hid which pharmacy compounded them.

What this means for you

  • A lower price on a compounded product is not the same product as the brand.
  • Look for a provider that names its pharmacy and is LegitScript-certified.
  • Be wary of any provider claiming compounded is "the same as" FDA-approved, that is exactly what regulators are penalizing.

How we label it

Every offer on this site is tagged FDA-approved or Compounded, and we surface each provider's certification and named pharmacy so you can decide with full information. Compare semaglutide providers →

This page is general information, not medical or legal advice. Regulations are changing; verify current status with a licensed clinician.